Bio-Native SaaS Platform
LensAI
One platform.
Multi-function access.
In-house intelligence. Out-sized capability.
With LensAI™ flexible SaaS, researchers gain direct access to a suite of multi-functional applications and tools within a single platform. From hit selection to lead refinement, it supports scale, integration, and efficient workflows across everyday discovery.
Screening
Applications
LensAI
Scalable SaaS platform for biologics exploration, discovery and design
Validated accuracy matching gold-standard X-ray crystallography.
Identify antibody binding sites with 3D precision.
Demonstrated effectiveness for ADA risk stratification.
Identify high-risk therapeutics.
Automated developability profiling from sequence data.
Evaluate stability, solubility, chemical liabilities, and non-specific binding considerations early.
Fully automated, scalable, and ready for use.
From preprocessing to post-analysis—with access to contact, affinity, trajectory data.
Hit selection with 360° biological insight.
Go beyond sequence to reveal structural, physicochemical, and functional relationships, clustering diverse antibodies with shared properties at scale.
Expand hits with functional precision.
Discover diverse, relevant sequences by comparing across sequence, structure, and physicochemical properties—all within one intelligent workflow.
Key benefits:
- Multi-functional tools: run diverse applications in one platform. Hit Expansion, Immunogenicity and more…
- Continuously enriched: new datasets are added as programs evolve, informing your project with expanding intelligence.
- Scalable access: expand from small projects to large studies, without added infrastructure.
Send us your data, whether sequence, structure, or complete program context, and see LensAI in action. With minimal integration, LensAI provides connected biological insight. Start with a paid pilot, measure the results, then scale to SaaS. A bio-native discovery ecosystem designed to deepen biological understanding, refine candidates, and support progress through discovery and development.
Subscription based
Discover the full scope of LensAI through a flexible subscription model, providing on-demand access to AI-native biological intelligence for applications such as epitope mapping, functional analysis, and scalable insight across each stage of discovery.
New FDA guidance: AI derived data now accepted in IND filings
In January 2025, the FDA clarified that AI-based findings can be part of IND submissions when they’re transparent, reproducible, and traceable. HYFTs® structure and connect complex data to meet those standards—turning AI insight into evidence ready for regulatory review.
One platform. Your workflow. Total flexibility.
See it in action
Request demo